Iteos Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for patients. They're engaging in the development of inupadenant and EOS-448, two small molecules used in clinical trials to promote dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity (ADCC). Founded in 2011, Iteos Therapeutics is based in Watertown, Massachusetts.